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Background: Vitamin B12 deficiency is common in older people, and may be responsible for reversible dementia.
Low serum vitamin B12 levels were also observed in patients with Mild Cognitive Impairment (MCI). It is not known
whether patients with vitamin B12 deficiency have a distinctive profile of cognitive impairment different from the
episodic memory deficit usually observed in MCI.
Results: From a cohort of 310 patients with MCI followed in a memory clinic in Lisbon, only 10 cases with vitamin
B12 deficiency were found. From collaboration with other neurologists, 5 further patients with vitamin B12
deficiency were added. These cases were compared to MCI patients with normal vitamin B12 levels in a ratio
1:3. The duration of subjective cognitive symptoms was significantly shorter in MCI patients with B12 deficiency
(1.2±1.0 years) as compared to MCI patients with normal vitamin B12 levels (3.4±3.0 years, p<0.001, Student’ t test).
There were no statistically significant differences in the neuropsychological tests between MCI patients with and
without vitamin B12 deficiency. Vitamin B12 was started in MCI patients with vitamin B12 deficiency, with no
noticeable clinical improvement.
Conclusion: MCI patients with low levels of vitamin B12 had no particular profile of cognitive impairment, however
vitamin B12 deficiency might have precipitated the onset of symptoms. The effect of vitamin B12 supplementation
in patients with MCI and low vitamin B12 levels should be clarified by future prospective studies.
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Neuropsychological testsBackground
Vitamin B12 deficiency is common in the elderly, affect-
ing as much as 10% to 15% of people over the age
of 60 as a consequence of inadequate intake or
malabsortion [1]. Vitamin B12 deficiency causes a clas-
sical neurological and hematological syndrome [2,3], and
has long been associated with cognitive and psychiatric
disturbances [4]. In a review of 32 studies, vitamin B12
deficiency was responsible for about 1% of the reversible
dementias [5].
More recently, vitamin B12 deficiency was also impli-
cated in milder forms of cognitive decline. In a* Correspondence: dinasilva@fm.ul.pt
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stated.consecutive series of patients observed in a memory
clinic, 3.3% of patients with Mild Cognitive Impairment
(MCI) had low serum values of vitamin B12 [6]. MCI is
usually considered a transitional state between normal
cognitive aging and dementia [7]. Although patients with
MCI may have involvement of different cognitive do-
mains, episodic memory is most consistently disturbed
[8]. It could be that patients with vitamin B12 deficiency
had a distinctive profile of cognitive impairment, since
cognitive domains other than memory were reported to
be affected by the deficiency of vitamin B12. In a previ-
ous study, non-demented cognitively impaired elderly
patients with vitamin B12 deficiency had lower verbal
fluency scores as compared with those with normal
values of vitamin B12 [9]. In a sample of non-demented
elderly subjects from a community based study, both
normal and cognitively impaired, the values of methyl-
malonic acid, which inversely reflect the levels ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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in language and praxis tests [10]. In another study
performed in non-demented elderly subjects, low con-
centrations of vitamin B12 were associated with poorer
performance in a spatial copying test [11]. Also in a sam-
ple of non-demented subjects older than 75, low levels of
vitamin B12 were associated with decreased performance
in a modified block design test, which evaluates
abstraction and visuospatial abilities [12]. Thus, different
cognitive domains were reported to be affected in non-
demented elderly subjects with vitamin B12 deficiency.
In the present study, we hypothesized that patients
with cognitive impairment and vitamin B12 deficiency
may have a particular profile of cognitive deficits that
could be different from the usual pattern of episodic
memory impairment observed in MCI patients. To test
this hypothesis, we compared the neuropsychological
performances of MCI patients with vitamin B12 defi-
ciency to neuropsychological performances of matched
MCI patients with normal serum vitamin B12 levels.
Recognition of a particular neuropsychological profile
could indicate preferential requirements or a particular
role for vitamin B12 in specific brain areas, and possibly
facilitate the detection of vitamin B12 deficiency in pa-
tients with MCI.
Methods
The database of a Memory Clinic in Lisbon was system-
atically searched for patients with the diagnosis of MCI
for the period 2002–2010. Since a limited number of pa-
tients with vitamin B12 deficiency was found, and for
the sake of an appropriate sample size, other neurolo-
gists (IS, IPM, AV) were requested and agreed to provide
cases with cognitive deficits and vitamin B12 deficiency.
All patients were observed in a dementia outpatient
clinic setting due to the presence of cognitive com-
plaints, and underwent a standard and comprehensive
neuropsychological assessment by the same neuropsy-
chologists (MG, DS, MV).
The study was approved by the Comissão de Ética
para a Saúde do Hospital de Santa Maria.
Inclusion criteria
Mild Cognitive Impairment was diagnosed according to
the criteria by the MCI Working Group of the European
Consortium on Alzheimer’s disease [13]:
1. Cognitive complaints coming from the patients or
their families;
2. Reporting of a decline in cognitive functioning
relative to previous abilities during the past year by
the patient or informant;
3. Objective impairment in memory or another
cognitive domain;4. Absence of major repercussions in daily life (the
patient may report difficulties concerning complex
day-to-day activities).
Vitamin B12 deficiency
Patients with MCI were considered to have vitamin B12
deficiency when vitamin B12 serum levels were less than
200 pg/mL, and to have normal vitamin B12 if the
serum levels were equal or higher than 200 pg/mL
[14,15].
Selection of cases and controls
Clinical files of all MCI patients were reviewed at the
Memory Clinic in Lisbon (2002–2010). The cases with
vitamin B12 deficiency were selected. Cases with vitamin
B12 deficiency and neuropsychological assessment re-
ferred from the other participating neurologists were
also included. For each patient presenting vitamin B12
deficiency, 3 MCI subjects with normal levels of vitamin
B12, matched for gender, education and age (± 2 years),
were consecutively selected for controls from the clinical
files of the Memory Clinic. The selection ratio 1:3 en-
hanced the power to detect differences in the neuro-
psychological tests between the two groups, given a
limited number of patients with vitamin B12 deficiency.
Exclusion criteria
1. Diagnosis of neurological or psychiatric disorders
that might justify the cognitive deficits associated to
the MCI condition;
2. History of alcohol abuse or recurrent substance
abuse or dependence;
3. Systemic illness with cerebral involvement,
untreated endocrine disorders, metabolic deficits
other than vitamin B12 (for instance folate
deficiency);
4. Presence of dementia according to DSM-IV-TR [16];
5. Vitamin B12 levels not obtained or not recorded.
Neuropsychological assessment
The detailed neuropsychological assessment was carried
out by the same team of trained neuropsychologists with
the Battery of Lisbon for the Assessment of Dementia
(BLAD) [17], a comprehensive neuropsychological bat-
tery evaluating multiple cognitive domains and validated
for the Portuguese population. This battery includes
tests for the following cognitive domains: attention and
executive functions (Cancellation Task, Digit Span back-
ward and Clock Draw); initiative (Verbal Semantic
Fluency, Motor Initiative and Graphomotor Initiative);
conceptual thinking (Raven Progressive Matrices and
Interpretation of Proverbs); calculation (Basic Written
Calculation); language (a modified version of the Token
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tation Questionnaire); immediate memory (Digit Span
forward); episodic memory and associative learning
(Verbal Paired-associate Learning, Logical Memory and
Word Recall). A Forgetting Index was also calculated
based on the correct information evoked between the
immediate and the delayed condition of the Logical
Memory Test (Forgetting Index= [(LM delayed recall –
LM immediate) / LM immediate)] × 100) [18].
Depressive symptoms were evaluated with the Geriatric
Depression Scale (GDS) [19,20], a self-report assessment
used specifically to identify depression in the elderly. For
this study a short-form (15 items) of the self-report instru-
ment was used [21].Statistical analyses
The sample size was calculated to test the hypothesis
that patients with vitamin B12 deficiency have less defi-
cits in episodic memory as compared to typical patients
with MCI. In a previous paper, we found that patients
with MCI had a score in Logical Memory (immediate re-
call) of −1.74±0.89 (z score) [22]. Assuming that patients
with vitamin B12 deficiency would score higher than −1
SD, and for a significance level of 0.05, a power of 0.80
and a ratio B12 deficiency:control of 1:3, a total sample
size of 60 (15:45) would be needed [23].
The presence of statistically significant differences be-
tween groups in demographic and clinical data was
analysed using Student’s t test for numerical data and
the Fisher’s exact test for categorical data. Since several
neuropsychological tests scores did not follow the nor-
mal distribution, the Mann–Whitney test was used to
compare performances in neuropsychological tests of
MCI patients with and without B12 deficiency. No cor-
rection for multiple comparisons was done. Statistical
significance was set at p values < 0.05. All statistical ana-
lyses were performed using SPSS for Windows (PASW
Statistics 18; SPSS Inc, Chicago, USA).Table 1 Demographic and clinical data of patients with Mild
with patients with MCI and normal vitamin B12 levels
Age, years [mean ± SD (range)]
Sex, female/male (n)
Formal education, years (mean ± SD)
Vitamin B12 level, pg/mL (mean ± SD)
Duration of cognitive complaints (mean ± SD)
Depressive symptoms, geriatric depression scale (mean ± SD)
Drugs with possible effect on cognition (n)
Response to vitamin B12 therapy, Yes/No/Unknown (n)
‡Student’s t-test, †Fisher’s exact test; *Statistically significant (p< 0.05), NA not applicResults
The clinical files of 310 patients with the diagnosis of
MCI evaluated in a Memory Clinic in Lisbon were
reviewed. Only 10 MCI patients with B12 deficiency
were found. It was possible to add 5 further cases of
MCI patients with vitamin B12 deficiency from the other
participant neurologists to achieve the sample size
needed for the power and significance established. None
of these cases had anemia or neurological symptoms
other than cognitive.
Demographic data are shown in Table 1, no statisti-
cally significant differences being found between MCI
patients with B12 deficiency and MCI patients with nor-
mal vitamin B12 levels, as expected from the matching
procedure. The duration of cognitive symptoms was sig-
nificantly shorter in MCI patients with B12 deficiency
(1.2±1.0 years) as compared to MCI patients with nor-
mal vitamin B12 levels (3.4±3.0 years, p<0.001, Student’
t test, Table 1). There were no significant differences
concerning the presence of depressive symptoms and
the prescription of drugs with possible interference on
cognition, namely anticholinergic effects (Table 1). As
expected, the levels of serum vitamin B12 were signifi-
cantly different between the two groups (p<0.001, Stu-
dent’ t test, Table 1).
The results of the neuropsychological tests of MCI pa-
tients with vitamin B12 deficiency were compared with
the results of matched MCI patients with normal vita-
min B12 levels, and no statistically significant differences
were found, even without adjusting the significance
levels for multiple comparisons (Table 2). The most pro-
nounced deficits were found in memory tests and orien-
tation, for both groups (Table 2).
Vitamin B12 therapy was started in all MCI patients
with vitamin B12 deficiency (1 mg orally every day or 1
mg by intramuscular administration every month) and
the normalization of serum levels was obtained. How-
ever, the clinical follow-up (6 months to 3 year after















Table 2 Comparison of the neuropsychological performances of MCI patients with vitamin B12 deficiency with the
performances of MCI patients with normal vitamin B12 levels
Cognitive domain MCI vitamin B12 deficiency (n=15) MCI normal vitamin B12 (n=45) p – value‡
Neuropsychological tests # mean ± SD # mean ± SD
Attention and executive functions
Cancellation task −0.004±0.98 0.07±0.97 0.90
Digit span backward 0.78±1.07 0.24±0.72 0.13
Clock draw 0.80±0.71 0.59±0.89 0.84
Initiative
Verbal semantic fluency −0.22±1.40 −0.55±1.40 0.30
Motor initiative 0.59±0.57 0.12±1.40 0.51
Graphomotor initiative 0.24±0.50 0.10±0.71 0.58
Conceptual thinking
Raven progressive matrices −0.08±0.90 0.10±0.97 0.62
Interpretation of proverbs 1.03±0.68 0.36±1.00 0.09
Calculation
Basic written calculation −0.18±0.78 −0.16±1.08 0.62
Language
Token test 0.24±1.05 −0.12±1.51 0.74
Orientation
Personal, spatial and temporal −1.99±2.76 −1.67±2.29 0.88
Immediate memory
Digit span forward 0.87±1.52 0.64±1.34 0.71
Episodic memory and associative learning
Verbal paired-associate learning −0.70±1.23 −1.42±0.65 0.11
Logical Memory (LM; immediate recall) −1.37±1.43 −1.64±0.93 0.46
Word recall −0.89±1.11 −1.30±1.24 0.45
Forgetting index† −1.26±0.97 −0.67±2.34 0.55
# z scores are shown; data are standardized according to the age and education norms from the Portuguese population.
† Forgetting Index = [(LM delayed recall – LM immediate) / LM immediate)]*100.
‡ Mann–Whitney test.
Silva et al. BMC Research Notes 2013, 6:357 Page 4 of 6
http://www.biomedcentral.com/1756-0500/6/357lost to follow-up) did not show clinical benefits from
vitamin B12 therapy.Discussion
Patients with MCI and vitamin B12 deficiency had no
particular profile of cognitive impairment that would be
distinct from that usually observed in MCI patients with
normal vitamin B12 levels. Episodic memory and orien-
tation were predominantely affected in MCI patients
with vitamin B12 deficiency, which are the cognitive do-
mains typically altered in MCI patients [7,8]. On the
other hand, cognitive domains previously reported to be
disturbed by vitamin B12 deficiency, namely verbal flu-
ency [9], language and praxis [10], and abstraction and
visuospatial abilities [11,12] were not more impaired in
MCI patients with vitamin B12 deficiency as compared
to MCI patients with normal vitamin B12 levels.Several cross-sectional and longitudinal studies in both
healthy and cognitively impaired older subjects reported in-
verse associations between vitamin B12 levels and the de-
gree of cognitive impairment [24-27], whereas other studies
found no association [28-31]. Moreover, a recent review
found that vitamin B12 deficiency is associated with cogni-
tive impairment, but supplementation did not improve cog-
nitive function in patients with previous deficits [32].
The benefit of vitamin B12 therapy regarding cogni-
tion is presently not clear. There are reports of patients
with cognitive deficits who improved, namely in
language and frontal lobe functions, after vitamin B12
supplementation [9]. However, the hypothesis that sup-
plementation of vitamin B12, together with other vita-
mins, could have beneficial cognitive effects in subjects
with normal or impaired cognition was not demon-
strated neither in a randomized controlled trial [33] nor
in a recent systematic review and meta-analysis [34].
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presence of low levels of vitamin B12 in age-associated
cognitive impairment might be an epiphenomenon, or a
consequence of disease progression, rather than the
cause of cognitive decline [26,35-37]. In the present
study, the finding of similar neuropsychological profiles
for MCI patients with low vitamin B12 levels, as com-
pared to those with normal levels, would suggest that
low vitamin B12 was just an incidental finding. This in-
terpretation was also supported by the observation that
the patients with vitamin B12 deficiency prescribed high
doses of vitamin B12 (either oral or intramuscular see
[38,39]), did not clinically improve, even though the dur-
ation of cognitive symptoms before supplementation
was within the time window (about 1 year) proposed for
a successful supplementation therapy [40,41]. On the
other hand, the finding of a shorter duration of clinical
symptoms in MCI patients with vitamin B12 deficiency
may suggest that this metabolic disturbance could some-
how have precipitated the onset, or even accelerated the
progression, of cognitive symptoms in patients diag-
nosed with MCI.
Limitations of the study should be recognized. It had a
retrospective design, which might have introduced a se-
lection bias, and would not allow the recognition of a
possible distinct clinical evolution for the MCI patients
with vitamin B12 deficiency. Regarding the effect of vita-
min B12 supplementation, one patient had no follow-up
information, and others might not have been followed
long enough to detect a sizeable response to therapy.
Also, a formal neuropsychological re-assessment was
not performed which might detect eventual subtle im-
provements in some cognitive tests after vitamin B12
supplementation.
Another limitation is that methylmalonic acid, which
may reflect more closely the physiological role of vita-
min B12, was not quantified. Since conversion of
methylmalonyl-coenzyme A to succinyl-coenzyme A
depends upon vitamin B12, increased levels of
methylmalonic acid are considered a sensitive and spe-
cific marker for functional vitamin B12 deficiency [10].
It is interesting to note that, in spite of vitamin B12
being tested as part of the standard laboratory diagnostic
workup for patients with cognitive complaints at the
Memory Clinic in Lisbon, only 3.2% of all MCI patients
observed in this institution during the period of 2002 to
2012 had decreased serum values of vitamin B12,
confirming a low frequency of vitamin B12 deficiency in
MCI patients [6]. Nowadays, in clinical practice, the
prevalence of reversible dementias is declining [42] and
the identified metabolic abnormalities are often not the
main cause responsible for the cognitive symptoms when
compared with the neurodegenerative pathology [43].
Nevertheless, detection of a metabolic disturbance, likevitamin B12 deficiency, is still advisable, since it might
contribute to cognitive deterioration in individual cases
and is usually amenable to correction. Moreover, vitamin
B12 deficiency appears to precipitate the onset of symp-
toms in patients with MCI. The effect of vitamin B12 sup-
plementation in patients with MCI and low vitamin B12
levels should be clarified by future prospective studies.
Conclusions
The profile of cognitive impairment in MCI patients
with and without vitamin B12 deficiency was similar,
suggesting that the finding of low vitamin B12 serum
levels in some cases of MCI could be just coincidental.
Interestingly, the MCI patients with low vitamin B12
serum levels had a shorter duration of clinical symptoms
than MCI patients with normal levels of vitamin B12,
raising the hypothesis that this metabolic disturbance
could have somehow precipitated the onset of cognitive
symptoms in those patients. Future prospective studies
are needed to clarify the effect of vitamin B12 supple-
mentation on the clinical progression of patients with
MCI and low vitamin B12 levels.
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